Cost-effectiveness analysis of stereotactic ablative radiotherapy in patients with oligometastatic cancer.

Abhishek Kumar,Christopher Straka,Lucas K. Vitzthum,Daniel R Cherry,Patrick Travis Courtney,Paul Riviere,James D. Murphy

Cost-effectiveness analysis of stereotactic ablative radiotherapy in patients with oligometastatic cancer.

2020

Abhishek Kumar
Christopher Straka
Lucas K. Vitzthum
Daniel R Cherry
Patrick Travis Courtney
Paul Riviere
James D. Murphy

7085Background: The SABR-COMET randomized clinical trial found that stereotactic ablative radiotherapy (SABR) improved outcomes among cancer patients with oligometastatic disease. Yet, the cost of ...

Keywords:

Cancer
Cost-effectiveness analysis
Radiology
Physical therapy
Ablative case
in patient
Radiation therapy
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations